Shaperon to Conduct Strategic Partnering and Institutional Investor Meetings at the 10th Annual BFC Healthcare Business Development & Investment Conference in Shanghai

SHANGHAI & SEOUL, South Korea & CAMBRIDGE, Mass.–(BUSINESS WIRE)–Shaperon, Inc. (Kosdaq: 378800), a biotechnology company dedicated to developing innovative immunology and immuno-oncology drugs, announced it had been invited by BFC Group to participate in the upcoming 10th Annual BFC Healthcare Business Development & Investment Conference. Scheduled to take place in Shanghai, China, this prestigious event will provide a platform for extensive business collaboration and investment opportunities in the expansive pharmaceutical and biotech sector. Shaperon plans to have meetings with top pharmaceutical and biotech companies in China and in the world during the event this year.

Shaperon is actively seeking to broaden its international presence. The company aims to secure licensing partners, attract potential strategic and institutional investors, and explore new business collaborations, particularly within the dynamic Chinese market. As part of its strategy, Shaperon has planned thirty partnering meetings with leading pharmaceutical and biotech companies in China to discuss licensing out opportunities for its innovative pipelines.

Janice Marie McCourt, CEO of Hudson Therapeutics, Inc., the US subsidiary of Shaperon, expressed enthusiasm about the seminar and the scheduled business meetings, stating, “Participating in the 10th BFC Seminar marks a significant milestone for Shaperon. Following our expansion into the global arena and the establishment of Hudson Therapeutics in the USA, we have actively extended our outreach beyond Korea. We have recently completed enrollment for cohort one in the Phase 2b clinical trial in the US of our atopic dermatitis treatment, ‘Nugel,’. This conference not only allows us to showcase our advanced biomedical innovations but also perfectly aligns with our strategy to penetrate Asian markets, especially China, where there is a rapidly growing demand for advanced healthcare solutions.”

ABOUT SHAPERON

Shaperon is a clinical stage biotech company developing novel inflammasome inhibitors. Its unique mechanism of action of GPCR19-P2X7 modulation suppresses a broad spectrum of inflammatory cytokines including IL-1β, IL-18, IL-6, and TNF-α by controlling both priming and activation phase of inflammasome, whereas conventional approaches are designed to suppress only the activation phase. With this unique and novel modality which is best suited to address complex immune-mediated inflammatory disorders, Shaperon is currently developing multiple clinical programs in atopic dermatitis, Alzheimer’s disease, and COVID 19 pneumonia in addition to pre-clinical pipelines, including MASH and obesity programs.. Shaperon is also developing its immuno-oncology pipelines, such as bi-specific and tri-specific nanobodies based on its propritory nanobody platform technology.

ABOUT Hudson Therapeutics

Hudson Therapeutics, a US subsidiary of Shaperon was founded and incorporated in the US in 2023 to lead global clinical trials, investor relations, commercial strategy, and business development of assets from Shaperon. Hudson also plans to develop Shaperon’s early-stage assets in the future.

Contacts

Ellie Jung

ellie@hudsontherapeutics.com